INGN - Inogen, Inc.
Shares of Inogen, Inc (NASDAQ: INGN - Get Free Report) passed above its fifty day moving average during trading on Friday. The stock has a fifty day moving average of $5.61 and traded as high as $6.28. Inogen shares last traded at $6.18, with a volume of 243,801 shares traded. Analyst Upgrades and Downgrades Separately, Weiss
BEVERLY, Mass.--(BUSINESS WIRE)---- $INGN #AirwayClearance--INOGEN ANNOUNCES DIVESTITURE OF ITS U.S. OXYGEN RENTAL BUSINESS TO ROTECH.
INGN's POC demand, new products and international growth support its outlook, while U.S. channel shifts and distributor timing pose risks.
Dimensional Fund Advisors LP decreased its holdings in Inogen, Inc (NASDAQ: INGN) by 28.3% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 509,822 shares of the medical technology company's stock after selling 201,558 shares during the period. Dimensional Fund
Inogen's steep sales-multiple discount, improving margins and firm international demand clash with U.S. sales and rental weakness.
INGN cuts its 2026 revenue outlook as U.S. channel pressure weighs, while international growth, new products and cost control offer support.
INGN's Q2 revenues rise 3% as international sales climb 14.8%, but U.S. weakness led it to cut its 2026 revenue outlook.
Inogen, Inc. (INGN) Q2 2026 Earnings Call Transcript
Inogen NASDAQ: INGN reported second-quarter 2026 revenue of $95.1 million, up 3% from a year earlier, as international growth, portable oxygen concentrator demand and contributions from newer products offset continued pressure in its U.S. direct-to-consumer business.
Inogen (INGN) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $0.15 per share a year ago.
BEVERLY, Mass.--(BUSINESS WIRE)---- $INGN #AirwayClearance--Reported second quarter revenue of $95.1 million. Company raises full-year adjusted EBITDA guidance to approximately $4.0 million.
BEVERLY, Mass.--(BUSINESS WIRE)---- $INGN #AirwayClearance--Inogen to Report Second Quarter 2026 Financial Results on August 6, 2026.
BEVERLY, Mass.--(BUSINESS WIRE)---- $INGN #AirwayClearance--Inogen Announces the Appointment of Andy Reding as Chief Operating Officer.
INGN's POC strength, expanding respiratory portfolio and international momentum support growth, though U.S. revenue pressure remains a key risk.
INGN broadens beyond portable oxygen concentrators into home respiratory care, but U.S. revenues face pressure from channel shifts.
Inogen, Inc. (INGN) Q1 2026 Earnings Call Transcript
Inogen posts higher Q1 revenues and improved gross margin as international portable oxygen demand offsets weaker U.S. sales.
Inogen (INGN) came out with a quarterly loss of $0.3 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to a loss of $0.25 per share a year ago.
BEVERLY, Mass.--(BUSINESS WIRE)---- $INGN #AirwayClearance--Inogen Announces First Quarter 2026 Financial Results.
Inogen, Inc (NASDAQ: INGN - Get Free Report) shares crossed above its fifty day moving average during trading on Thursday. The stock has a fifty day moving average of $6.29 and traded as high as $7.38. Inogen shares last traded at $6.99, with a volume of 201,150 shares traded. Analyst Ratings Changes Separately, Freedom Capital